A fierce battle for market share in hepatitis C treatment is taking a toll on Gilead Sciences’ financials, but a proposal to reform Obamacare may offer a tailwind friendly to the bottom line.
Congress is proposing a repeal of Obamacare and, as part of that effort, a jettisoning of the taxes associated with it. If this replacement plan becomes law, then it could add hundreds of millions of dollars to the company’s annual profits.
Give me a (tax) break
Obamacare includes a slate of taxes and fees to help offset its cost, and the branded prescription drug fee is one of them.
